New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort

被引:41
作者
Hoffman, Aviad [2 ,3 ]
Lazar, Alexander J. [3 ,4 ]
Pollock, Raphael E. [2 ,3 ]
Lev, Dina [1 ,3 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Sarcoma Res Ctr, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
关键词
Liposarcoma; Targeted therapy; MDM2; Dedifferentiation; Trabectedin; PPAR gamma; PI3K/AKT; SOFT-TISSUE SARCOMA; ACTIVATED RECEPTOR-GAMMA; PHASE-II TRIAL; ELECTRON-BEAM RADIOTHERAPY; ADJUVANT RADIATION-THERAPY; FOLLOW-UP ANALYSIS; FACTOR-KAPPA-B; WILD-TYPE P53; MYXOID LIPOSARCOMA; TLS-CHOP;
D O I
10.1016/j.drup.2010.11.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The adipogenic origin-derived liposarcoma (LPS) family is the most common soft tissue sarcoma histological subtype. This group is composed of three categories as per the 2002 WHO guidelines: (1) well-differentiated and dedifferentiated liposarcoma (WDLPS/DDLPS); (2) myxoid and round cell liposarcoma (MLS and RCL); and (3) pleomorphic liposarcoma (PLS). While clustered together, these histological subtypes are widely diverse in their clinical, pathological, and molecular characteristics. In general, surgery still remains the mainstay of LPS therapy and the only approach offering the potential of cure. Effective therapeutic strategies for locally advanced and metastatic disease are currently lacking and are crucially needed. With the current gradually increasing knowledge of LPS genetic- and epigenetic-associated deregulations, the ultimate goal is to develop drugs that can specifically eliminate LPS cells while sparing normal tissues. This tumor-tailored target-orientated approach will hopefully result in a significant improvement in the outcome of patients suffering from these poor prognosis malignancies. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:52 / 66
页数:15
相关论文
共 228 条
[1]   Human translocation liposarcoma CCAAT enhancer binding protein (C/EBP) homologous protein (TLS-CHOP) oncoprotein prevents adipocyte differentiation by directly interfering with C/EBPβ function [J].
Adelmant, G ;
Gilbert, JD ;
Freytag, SO .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (25) :15574-15581
[2]   Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours [J].
Aleixo, P. B. ;
Hartmann, A. A. ;
Menezes, I. C. ;
Meurer, R. T. ;
Oliveira, A. M. .
JOURNAL OF CLINICAL PATHOLOGY, 2009, 62 (12) :1127-1135
[3]   Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-kinase/AKT in breast cancer cells [J].
Altiok, S ;
Batt, D ;
Altiok, N ;
Papautsky, A ;
Downward, J ;
Roberts, TM ;
Avraham, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (45) :32274-32278
[4]   REARRANGEMENT OF THE TRANSCRIPTION FACTOR GENE CHOP IN MYXOID LIPOSARCOMAS WITH T(12 16)(Q13 P11) [J].
AMAN, P ;
RON, D ;
MANDAHL, N ;
FIORETOS, T ;
HEIM, S ;
ARHEDEN, K ;
WILLEN, H ;
RYDHOLM, A ;
MITELMAN, F .
GENES CHROMOSOMES & CANCER, 1992, 5 (04) :278-285
[5]  
[Anonymous], CURR OPIN PHARM
[6]  
[Anonymous], J CLIN ONCOL
[7]  
[Anonymous], ASCO ANN M
[8]  
[Anonymous], 1997, ADV ANAT PATHOL, DOI DOI 10.1097/00125480-199703000-00005
[9]  
[Anonymous], 2008, ENZINGER WEISSS SOFT
[10]  
[Anonymous], 2003, Cochrane Database Syst Rev, DOI DOI 10.1002/14651858.CD003293